Patents by Inventor Dale J. Christensen
Dale J. Christensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230270668Abstract: The invention generally encompasses a human-derived monoclonal antibody compositions and methods comprising a dry powder formulation for neutralizing SARS-CoV-2 and known variants thereof in a patient, comprising administering to the patient a dry powder formulation comprising the human-derived monoclonal antibody. The invention further encompasses compositions and methods comprising a dry powder formulation for treating or preventing COVID-19 and/or at least one symptom associated with COVID-19 in a patient, comprising administering to the patient a dry powder formulation comprising the human-derived monoclonal antib.Type: ApplicationFiled: October 11, 2022Publication date: August 31, 2023Inventors: Christopher J. EMIG, Steven J. HENRY, Adela Anne VITUG, Dale J. CHRISTENSEN, Zhengrong CUI, Haiyue XU, Robert O. WILLIAMS, III
-
Publication number: 20230190735Abstract: The invention generally encompasses compositions and methods including inhalable voriconazole or a pharmaceutically acceptable salt thereof manufactured in amorphous form using thin film freezing. In various embodiments, the invention includes a dry powder voriconazole formulation that can be inhaled, for example, using a dry powder inhaler, and is well tolerated as a daily regimen for treating or preventing fungal infections. The compositions and methods of the invention avoid or reduce the systemic circulation of voriconazole and accordingly overcome the adverse events associated circulating voriconazole.Type: ApplicationFiled: December 16, 2022Publication date: June 22, 2023Inventors: Dale J. Christensen, John Koleng
-
Publication number: 20220362222Abstract: The present disclosure provides methods of using and pharmaceutical compositions of tacrolimus that may be administered by inhalation once a day. These methods and compositions may be used to generate a blood plasma concentration of tacrolimus in a therapeutically effective range using only a single dose daily. Administration once daily may result in few adverse events and reduced side effects while increasing patient compliance.Type: ApplicationFiled: May 12, 2022Publication date: November 17, 2022Inventors: Dale J. Christensen, Christopher S. Crean, John J. Koleng
-
Publication number: 20200031866Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.Type: ApplicationFiled: September 29, 2017Publication date: January 30, 2020Inventors: Timothy Morgan Crowder, Dale J. Christensen, John Clayton Taylor
-
Publication number: 20190071468Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.Type: ApplicationFiled: September 12, 2018Publication date: March 7, 2019Inventors: Robert Tarran, Dale J. Christensen
-
Patent number: 10150796Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.Type: GrantFiled: May 10, 2017Date of Patent: December 11, 2018Assignees: University of North Carolina at Chapel Hill, Spyryx Biosciences, Inc.Inventors: Robert Tarran, Dale J. Christensen
-
Publication number: 20170327538Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.Type: ApplicationFiled: May 10, 2017Publication date: November 16, 2017Inventors: Robert Tarran, Dale J. Christensen
-
Patent number: 9815884Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.Type: GrantFiled: March 20, 2015Date of Patent: November 14, 2017Assignee: Cognosci, Inc.Inventors: Michael P. Vitek, Dale J. Christensen
-
Patent number: 9809640Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.Type: GrantFiled: October 6, 2015Date of Patent: November 7, 2017Assignee: Cognosci, Inc.Inventors: Michael P. Vitek, Dale J. Christensen
-
Patent number: 9796768Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.Type: GrantFiled: April 21, 2017Date of Patent: October 24, 2017Assignees: Spryx Biosciences, Inc., The University of North Carolina at Chapel HillInventors: Robert Tarran, Dale J. Christensen
-
Patent number: 9730979Abstract: The present invention provides methods for modulating SET activity by contacting SET with a binding agent such as an ApoE peptide derivative. In one embodiment of the invention, a pharmaceutical composition capable of modulating SET activity is administered to a patient for the treatment of an inflammatory or neurological condition. In another embodiment of the invention, compounds efficacious for the treatment of inflammatory and neurological conditions are identified by screening for a binding agent capable of competing with or inhibiting the binding of an ApoE derivative to SET.Type: GrantFiled: December 21, 2007Date of Patent: August 15, 2017Assignee: COGNOSCI, INC.Inventors: Michael P. Vitek, Dale J. Christensen, Jessica Oddo
-
Publication number: 20170226180Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.Type: ApplicationFiled: April 21, 2017Publication date: August 10, 2017Inventors: Robert Tarran, Dale J. Christensen
-
Publication number: 20160102121Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.Type: ApplicationFiled: October 8, 2015Publication date: April 14, 2016Inventors: Robert Tarran, Dale J. Christensen
-
Publication number: 20160096877Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.Type: ApplicationFiled: October 6, 2015Publication date: April 7, 2016Inventors: Michael P. VITEK, Dale J. CHRISTENSEN
-
Publication number: 20160008424Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.Type: ApplicationFiled: March 20, 2015Publication date: January 14, 2016Inventors: Michael P. VITEK, Dale J. CHRISTENSEN
-
Patent number: 8623601Abstract: Provided are methods of predicting or assessing the level of severity of cancer or cancer progression in a patient comprising measuring levels of SET expression in a biological sample from a patient and comparing levels of SET expression to a control sample or standard value. Methods for predicting or evaluating the efficacy of a SET therapeutic and kits comprising at least one reagent for measuring SET protein expression are also provided.Type: GrantFiled: July 13, 2012Date of Patent: January 7, 2014Assignees: Cognosci, Inc., Duke UniversityInventors: Michael P. Vitek, Dale J. Christensen, J. Brice Weinberg
-
Publication number: 20130018001Abstract: Provided are methods of predicting or assessing the level of severity of cancer or cancer progression in a patient comprising measuring levels of SET expression in a biological sample from a patient and comparing levels of SET expression to a control sample or standard value. Methods for predicting or evaluating the efficacy of a SET therapeutic and kits comprising at least one reagent for measuring SET protein expression are also provided.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Applicants: Duke University, Cognosci, Inc.Inventors: Michael P. Vitek, Dale J. Christensen, J. Brice Weinberg
-
Publication number: 20130005645Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.Type: ApplicationFiled: January 6, 2011Publication date: January 3, 2013Inventors: Michael P. VITEK, Dale J. Christensen
-
Publication number: 20110166079Abstract: Methods of treating chronic lympocytic leukemia, chronic myelogenous leukemia, and breast cancer in a subject by administering an ApoE peptide are disclosed.Type: ApplicationFiled: July 1, 2009Publication date: July 7, 2011Applicant: COGNOSCI, INC.Inventors: Michael P. Vitek, Dale J. Christensen
-
Publication number: 20100144627Abstract: The present invention provides methods for modulating SET activity by contacting SET with a binding agent such as an ApoE peptide derivative. In one embodiment of the invention, a pharmaceutical composition capable of modulating SET activity is administered to a patient for the treatment of an inflammatory or neurological condition. In another embodiment of the invention, compounds efficacious for the treatment of inflammatory and neurological conditions are identified by screening for a binding agent capable of competing with or inhibiting the binding of an ApoE derivative to SET.Type: ApplicationFiled: December 21, 2007Publication date: June 10, 2010Inventors: Michael P. Vitek, Dale J. Christensen, Jessica Oddo